Bayer Teams Up With Versant to Develop Stem-Cell Therapies

Bayer and U.S. healthcare investor Versant Ventures plan to establish a stem-cell research company called BlueRock Therapeutics, with initial joint funding of $225 million.

from WSJ.com: US Business http://ift.tt/2haPRyh
via IFTTT